These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Synergism between tissue-type plasminogen activator and a genetically engineered variant lacking the finger domain, the growth factor domain and the first kringle domain. Mattson C; Wikström K; Sterky C; Pohl G Thromb Haemost; 1991 Mar; 65(3):286-90. PubMed ID: 1710837 [TBL] [Abstract][Full Text] [Related]
5. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants. de Vries C; Veerman H; Nesheim ME; Pannekoek H Thromb Haemost; 1991 Mar; 65(3):280-5. PubMed ID: 1904654 [TBL] [Abstract][Full Text] [Related]
6. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA). Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847 [TBL] [Abstract][Full Text] [Related]
7. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138 [TBL] [Abstract][Full Text] [Related]
8. Fibrin affinity and clearance of t-PA deletion and substitution analogues. Johannessen M; Diness V; Pingel K; Petersen LC; Rao D; Lioubin P; O'Hara P; Mulvihill E Thromb Haemost; 1990 Feb; 63(1):54-9. PubMed ID: 2111048 [TBL] [Abstract][Full Text] [Related]
9. The role of the finger domain of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in initiation and progression of thrombolysis. Stringer HA; van Swieten P; Horrevoets AJ; Smilde A; Pannekoek H Thromb Haemost; 1994 Dec; 72(6):900-5. PubMed ID: 7740461 [TBL] [Abstract][Full Text] [Related]
10. Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits. Agnelli G; Pascucci C; Colucci M; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1992 Sep; 68(3):331-5. PubMed ID: 1440500 [TBL] [Abstract][Full Text] [Related]
11. Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator. Nelles L; Li XK; Vanlinthout I; De Cock F; Lijnen HR; Collen D Thromb Haemost; 1992 Apr; 67(4):445-52. PubMed ID: 1631793 [TBL] [Abstract][Full Text] [Related]
12. Structure and function of human tissue-type plasminogen activator (t-PA). van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031 [TBL] [Abstract][Full Text] [Related]
13. The effector roles of kringle 1 and kringle 2 in the enzymatic properties of recombinant tissue-type plasminogen activator as revealed by generation of recombinant molecules containing each kringle linked to the protease domain. Rydzewski A; Castellino FJ Arch Biochem Biophys; 1993 Jan; 300(1):472-82. PubMed ID: 8424682 [TBL] [Abstract][Full Text] [Related]
14. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. Lamba D; Bauer M; Huber R; Fischer S; Rudolph R; Kohnert U; Bode W J Mol Biol; 1996 Apr; 258(1):117-35. PubMed ID: 8613982 [TBL] [Abstract][Full Text] [Related]
15. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727 [TBL] [Abstract][Full Text] [Related]
16. [Molecular biology of tissue-type plasminogen activator (t-PA) and clinical application of recombinant t-PA]. Fukao H; Matsuo O Nihon Rinsho; 1993 Jun; 51(6):1620-6. PubMed ID: 8320841 [TBL] [Abstract][Full Text] [Related]
17. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator. Bakker AH; Nieuwenbroek NM; Verheijen JH Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642 [TBL] [Abstract][Full Text] [Related]
18. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains. Emeis JJ; Verheijen JH Arzneimittelforschung; 1992 Mar; 42(3):358-62. PubMed ID: 1497699 [TBL] [Abstract][Full Text] [Related]
19. Homology modeling of tissue-type plasminogen activator K1 domain and studies on the interactions between kringles and lysine. Wang G; Liu S; Xu X; Huang P; Huang C Chin J Biotechnol; 1998; 14(1):17-24. PubMed ID: 9759541 [TBL] [Abstract][Full Text] [Related]
20. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]